No abstract available
Publication types
-
Case Reports
-
Clinical Conference
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / secondary
-
Adenocarcinoma / therapy*
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Cecal Neoplasms / diagnosis*
-
Cecal Neoplasms / pathology
-
Cecal Neoplasms / therapy*
-
Cetuximab
-
Colectomy
-
Combined Modality Therapy
-
Diagnosis, Differential
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Humans
-
Immunohistochemistry
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / secondary
-
Male
-
Neoplasm Staging
-
Organoplatinum Compounds / therapeutic use
-
Palliative Care
-
Peritoneal Neoplasms / diagnosis
-
Peritoneal Neoplasms / secondary
-
Positron-Emission Tomography
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins p21(ras)
-
Pseudomyxoma Peritonei / diagnosis
-
Whole Body Imaging
-
ras Proteins / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
KRAS protein, human
-
Organoplatinum Compounds
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Bevacizumab
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins
-
Cetuximab
-
Leucovorin
-
Fluorouracil
-
Camptothecin
Supplementary concepts
-
Folfox protocol
-
IFL protocol